

Resource Summary Report

Generated by T1D on Sep 5, 2026

Columbia University Human Immune Monitoring Core Facility

RRID:SCR_016740

Type: Tool

Proper Citation

Columbia University Human Immune Monitoring Core Facility (RRID:SCR_016740)

Resource Information

URL: <http://cuhimc.org>

Proper Citation: Columbia University Human Immune Monitoring Core Facility (RRID:SCR_016740)

Description: Research core facility for advanced immunology studies including multiplex tissue and spatial analysis, high-parametric cytometry, single-cell sequencing, experimental design, sample processing, data acquisition and processing, data analysis and management.

Abbreviations: HIMC

Synonyms: Columbia University Human Immune Monitoring Core, Human Immune Monitoring Core at Columbia University, The Human Immune Monitoring Core (HIMC)

Resource Type: access service resource, core facility, service resource

Keywords: immunology, study, core, facility, Columbia, University

Availability: Commercially available

Resource Name: Columbia University Human Immune Monitoring Core Facility

Resource ID: SCR_016740

Record Creation Time: 20220129T080332+0000

Record Last Update: 20260904T000817+0000

Ratings and Alerts

No rating or validation information has been found for Columbia University Human Immune Monitoring Core Facility.

No alerts have been found for Columbia University Human Immune Monitoring Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Gatz SA, et al. (2026) Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcS??-ESMART Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1210.

Liu L, et al. (2023) Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. *Immunity*, 56(10), 2442.

Liu L, et al. (2023) Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking. *bioRxiv : the preprint server for biology*.

Gartrell RD, et al. (2022) Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. *Oncoimmunology*, 11(1), 2066767.

Schutt CR, et al. (2021) Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma. *Oncotarget*, 12(6), 534.

Hickman RA, et al. (2021) Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway. *Neuropathology and applied neurobiology*, 47(3), 415.

Alishetti S, et al. (2020) Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, 20(12), 3620.

Liu L, et al. (2020) Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*, 584(7821), 450.

Strikoudis A, et al. (2019) Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells. *Cell reports*, 27(12), 3709.

Parsonnet J, et al. (2010) Persistence survey of toxic shock syndrome toxin-1 producing *Staphylococcus aureus* and serum antibodies to this superantigen in five groups of menstruating women. *BMC infectious diseases*, 10, 249.